Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kuros Biosciences ( (CH:KURN) ) has issued an announcement.
Kuros Biosciences reported a 51% year-on-year increase in total product sales to USD 43.4 million for the first quarter of 2026, driven almost entirely by MagnetOs, which also grew 51% to USD 42.9 million. EBITDA improved to USD 2.9 million and adjusted EBITDA rose to USD 5.7 million with a 13.1% margin, while cash declined to USD 15.7 million as the company continued to invest in diversifying and optimizing its manufacturing capacity.
Commercial momentum was supported by strong growth in minimally invasive spine procedures and the extremities segment, underscoring broader surgeon adoption of MagnetOs beyond traditional open spine surgery. A new study in high-risk lumbar fusion patients showed an 87% overall fusion rate with MagnetOs Easypack Putty, and Kuros reported on-track progress with its new Alpharetta, Georgia manufacturing site and expansion of its Dutch facility, bolstering supply resilience and long-term growth prospects.
The most recent analyst rating on (CH:KURN) stock is a Buy with a CHF38.00 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
More about Kuros Biosciences
Kuros Biosciences is a Swiss-listed medical technology company focused on next-generation bone-healing biologics, with operations in the U.S., Switzerland and the Netherlands. Its flagship product, MagnetOs, is an advanced synthetic bone graft used in spinal, extremity and pelvic procedures, and has achieved broad international adoption across multiple surgical indications.
Average Trading Volume: 166,849
Technical Sentiment Signal: Hold
Current Market Cap: CHF959.3M
For a thorough assessment of KURN stock, go to TipRanks’ Stock Analysis page.